Form 4: IDEXX Laboratories Director Sophie V. Vandebroek Reports Stock Option Exercise and Sale

Director Sophie V. Vandebroek reports exercising stock options and selling shares of IDEXX Laboratories, Inc.

Summary

• On May 9, 2025, Sophie V. Vandebroek, a director of IDEXX Laboratories, Inc., exercised non-qualified stock options to purchase 1,279 shares of common stock at a price of $283.59 per share.
• Simultaneously, Ms. Vandebroek sold 1,279 shares of common stock at a price of $491.3411 per share.
• Following these transactions, Ms. Vandebroek directly owns 1,167 shares of IDEXX common stock.
• She also indirectly owns 8,173 shares through the Sophie V. Vandebroek Revocable Trust.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure of stock transactions by a company insider, which is common in publicly traded companies. It provides transparency to investors regarding the trading activities of company executives and directors.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders, ensuring transparency in the market.
• Similar filings are made by executives at companies like Zoetis (ZTS) and Heska (HSKA), which are direct competitors of IDEXX in the animal health industry.

Stakeholder Impact

• The transaction may have a minor impact on shareholders due to the change in ownership by a director.
• The impact is likely minimal as the number of shares involved is relatively small compared to the total outstanding shares of IDEXX.

Key Dates

Keywords

IDEXX Laboratories, Director, Stock Options, Form 4, Beneficial Ownership, Securities, Vandebroek, IDXX